Carta al Editor
Eficacia y seguridad de baricitinib en pacientes con artritis reumatoide y respuesta inadecuada a FAME convencionales sintéticos o biológicos: datos de un registro local
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry
Leído
9220
Vecesse ha leído el artículo
1359
Total PDF
7861
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 12 | 23 | 35 |
| 2025 5 | 377 | 67 | 444 |
| 2025 4 | 390 | 39 | 429 |
| 2025 3 | 440 | 41 | 481 |
| 2025 2 | 379 | 38 | 417 |
| 2025 1 | 363 | 36 | 399 |
| 2024 12 | 309 | 36 | 345 |
| 2024 11 | 332 | 73 | 405 |
| 2024 10 | 268 | 38 | 306 |
| 2024 9 | 322 | 16 | 338 |
| 2024 8 | 336 | 37 | 373 |
| 2024 7 | 465 | 36 | 501 |
| 2024 6 | 398 | 27 | 425 |
| 2024 5 | 435 | 38 | 473 |
| 2024 4 | 263 | 43 | 306 |
| 2024 3 | 210 | 29 | 239 |
| 2024 2 | 211 | 30 | 241 |
| 2024 1 | 186 | 35 | 221 |
| 2023 12 | 171 | 19 | 190 |
| 2023 11 | 161 | 41 | 202 |
| 2023 10 | 186 | 57 | 243 |
| 2023 9 | 222 | 47 | 269 |
| 2023 8 | 149 | 19 | 168 |
| 2023 7 | 104 | 48 | 152 |
| 2023 6 | 105 | 33 | 138 |
| 2023 5 | 130 | 33 | 163 |
| 2023 4 | 77 | 29 | 106 |
| 2023 3 | 137 | 31 | 168 |
| 2023 2 | 84 | 35 | 119 |
| 2022 1 | 76 | 39 | 115 |
| 2022 12 | 112 | 60 | 172 |
| 2022 11 | 90 | 34 | 124 |
| 2022 10 | 162 | 36 | 198 |
| 2022 9 | 121 | 63 | 184 |
| 2022 8 | 6 | 6 | 12 |
| 2022 7 | 2 | 2 | 4 |
| 2022 6 | 6 | 0 | 6 |
| 2022 4 | 1 | 2 | 3 |
| 2022 3 | 10 | 6 | 16 |
| 2021 1 | 1 | 0 | 1 |
| 2021 11 | 2 | 2 | 4 |
| 2021 10 | 1 | 2 | 3 |
| 2021 9 | 6 | 4 | 10 |
| 2021 6 | 4 | 6 | 10 |
| 2021 5 | 3 | 2 | 5 |
| 2021 4 | 2 | 3 | 5 |
| 2021 3 | 8 | 2 | 10 |
| 2020 11 | 7 | 4 | 11 |
| 2020 10 | 1 | 2 | 3 |
| 2020 9 | 4 | 2 | 6 |
| 2020 7 | 6 | 2 | 8 |
| 2020 6 | 8 | 6 | 14 |
Mostrar todo
